This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01441/identifier/pubchem-compound/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/mesh/concept/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01441/identifier/pubchem-substance/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01441/identifier/drugbank/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01441/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB01441/identifier/wikipedia/

Statements

Subject Item
n2:DB01441
rdf:type
n3:Drug
n3:description
5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) is a tryptamine derivative and shares many similarities with schedule I tryptamine hallucinogens such as alpha-ethyltryptamine, N,N-dimethyltryptamine, N,N-diethyltryptamine, bufotenine, psilocybin and psilocin. Since 1999, there has been a growing popularity of 5-MeO-DIPT among drug abusers. This substance is abused for its hallucinogenic effects.
n3:generalReferences
# DEA "Link":http://www.deadiversion.usdoj.gov/drugs_concern/5meodipt.htm
n3:group
illicit experimental
owl:sameAs
n11:DB01441 n13:DB01441
dcterms:title
5-Methoxy-N,N-diisopropyltryptamine
adms:identifier
n9:133247 n12:DB01441 n14:151182 n15:46506676 n16:5-Methoxy-diisopropyltryptamine
n3:synonym
5-MeO-DIPT 5-methoxy-N,N-bis(1-methylethyl)-1H-Indole-3-ethanamine Foxy Foxy methoxy
n6:hasConcept
n7:M0104429
n3:IUPAC-Name
n4:271B4B8C-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4B92-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4B91-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4B8E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4B8F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4B90-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4B8A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4B88-363D-11E5-9242-09173F13E4C5 n4:271B4B8B-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4B89-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4B98-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4B99-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4B93-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4B94-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4B96-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4B95-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4B97-363D-11E5-9242-09173F13E4C5
n3:absorption
5-MeO-DIPT produces effects with an onset of 20 to 30 minutes and with peak effects occurring between 1 to 1.5 hours after administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
4021-34-5
n3:Bioavailability
n4:271B4B9E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4BA0-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4BA1-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4BA2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4B9D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4B9C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4B9F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4B8D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4B9A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4B9B-363D-11E5-9242-09173F13E4C5